WearOptimo, a healthcare technology company focused on next-generation microwearable sensors for hydration and biomarker monitoring, announced that it has received three additional patents, bringing its total granted patents to fifteen. These new patents cover critical enhancements to WearOptimo’s proprietary AI system, which powers the platform’s health insights, supports theranostic functions to move from sensing to potential therapy based on detected biomarkers, and expands the range of sensor applications.
Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India
Dr. Robert Langer, Institute Professor at MIT and Advisory Board Member of WearOptimo, said the company has created one of the most advanced microneedle sensor platforms available. He highlighted that WearOptimo’s patent portfolio is extensive and strategically designed, covering sensor design, AI analytics, scalable manufacturing, and theranostic capabilities. According to Dr. Langer, this comprehensive intellectual property protection provides the company with a rare and meaningful long-term competitive advantage while positioning its sensors for global expansion across multiple high-value healthcare applications.
Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk
Dr. Mark Kendall, CEO and Founder of WearOptimo, explained that the new patents are a key milestone in realizing the full potential of the microwearable platform. He emphasized that the patents strengthen the company’s ability to expand beyond hydration monitoring into clinical-grade applications, including devices that can detect biochemical signals related to serious conditions such as heart injury or cardiac events. Dr. Kendall reiterated that WearOptimo aims to build a platform that spans both the wellness sector and the medical device market, and the latest patents bring the company closer to that goal.
WearOptimo’s intellectual property now includes nine patent families with forty-five filings worldwide, fifteen of which have been granted. The company has secured protection in all major markets, including the United States, Europe, Australia, Japan, Canada, and China, ensuring broad coverage in its most important regions.
The company’s integrated IP portfolio covers microneedle sensor technology, AI-driven health analytics, and scalable manufacturing processes. Together, these patents create a strong protective barrier for the core platform while enabling WearOptimo to expand into future applications for disease and biochemical monitoring. This combination of technology and intellectual property positions the company for growth as it moves closer to commercializing its innovative microwearable sensors.
Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
